Jefferies Financial Group Equities Analysts Raise Earnings Estimates for Affimed NV (NASDAQ:AFMD)

Affimed NV (NASDAQ:AFMD) – Equities researchers at Jefferies Financial Group increased their Q2 2020 earnings per share (EPS) estimates for shares of Affimed in a report released on Wednesday, June 24th. Jefferies Financial Group analyst M. Raycroft now expects that the biopharmaceutical company will post earnings per share of ($0.14) for the quarter, up from their prior forecast of ($0.28). Jefferies Financial Group also issued estimates for Affimed’s Q3 2020 earnings at ($0.19) EPS, Q4 2020 earnings at ($0.18) EPS, FY2020 earnings at ($0.63) EPS, FY2023 earnings at ($0.15) EPS and FY2024 earnings at $0.02 EPS.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings data on Tuesday, June 23rd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The firm had revenue of $5.66 million during the quarter, compared to the consensus estimate of $8.51 million. Affimed had a negative return on equity of 135.08% and a negative net margin of 280.35%.

A number of other research analysts also recently issued reports on the company. Zacks Investment Research upgraded Affimed from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Tuesday. BidaskClub raised Affimed from a “hold” rating to a “buy” rating in a research report on Wednesday, June 24th. Finally, SVB Leerink upped their price target on Affimed from $7.00 to $8.00 and gave the company an “outperform” rating in a research report on Wednesday, June 24th. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $7.67.

Shares of NASDAQ:AFMD opened at $4.62 on Monday. The company has a market capitalization of $342.32 million, a PE ratio of -6.79 and a beta of 2.77. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.01 and a quick ratio of 3.00. The business has a fifty day moving average price of $3.30 and a two-hundred day moving average price of $2.60. Affimed has a 1 year low of $1.42 and a 1 year high of $4.77.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. lifted its holdings in Affimed by 240.0% during the 4th quarter. Point72 Asset Management L.P. now owns 1,700,000 shares of the biopharmaceutical company’s stock worth $4,658,000 after purchasing an additional 1,200,000 shares in the last quarter. State Street Corp lifted its holdings in Affimed by 6.9% during the 1st quarter. State Street Corp now owns 1,190,695 shares of the biopharmaceutical company’s stock worth $1,881,000 after purchasing an additional 76,878 shares in the last quarter. AQR Capital Management LLC lifted its holdings in Affimed by 3.3% during the 1st quarter. AQR Capital Management LLC now owns 1,097,885 shares of the biopharmaceutical company’s stock worth $1,735,000 after purchasing an additional 34,994 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Affimed by 18.7% during the 4th quarter. Geode Capital Management LLC now owns 661,081 shares of the biopharmaceutical company’s stock worth $1,811,000 after purchasing an additional 104,289 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Affimed by 10.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 337,273 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 30,930 shares in the last quarter. 50.88% of the stock is currently owned by institutional investors and hedge funds.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Read More: Profit margin is different from the revenue

Earnings History and Estimates for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.